[Which imaging in patients with low back pain ?] / Patient lombalgique : quel examen d'imagerie choisir ?

Low back pain is a major public health problem, with a significant physical and psychosocial impact. Inappropriate use of diagnostic imaging is one of the main factors contributing to the costs of these conditions. In addition, there is evidence to suggest that imaging and the accompanying report are risk factors for chronicity. This article reviews the main clinical situations that clinicians face and summarizes the good clinical practice recommendations for each of them.

Les lombalgies sont un véritable problème de santé publique, avec un impact physique et psychosocial important. L'utilisation inappropriée de l'imagerie fait partie des principaux facteurs qui participent aux coûts engendrés par ces pathologies. De plus, il existe des indices pour penser que la réalisation d'un examen d'imagerie et les éléments contenus dans le rapport qui l'accompagne sont des facteurs de risque de chronicité. Cet article aborde les principales situations cliniques auxquelles les cliniciens sont confrontés et résume les recommandations de bonnes pratiques pour chacune d'elles.

Incidence of COVID-19 in patients treated with infliximab compared with patients treated with rituximab.

OBJECTIVE: To determine whether patients with inflammatory autoimmune diseases treated with rituximab (RTX) have more severe forms of COVID-19 compared with patients treated with anticytokine therapies, such as Tumour Necrosis Factor (TNF) inhibitors. METHODS: We included all patients who were on either RTX or infliximab (IFX) in two Swiss cantons during the first wave of the COVID-19 pandemic. We collected self-reported symptoms compatible with COVID-19, PCR-confirmed diagnoses of COVID-19 and the evolution of COVID-19 infections. We computed the raw and propensity score-adjusted incidence of COVID-19 by treatment group. RESULTS: 190 patients were enrolled, of whom 121 (64%) were in the RTX group and 69 (36%) were in the IFX group. Twenty-one patients (11%) reported symptoms compatible with COVID-19 (RTX: 10, IFX: 11, p=0.14). Among patients with COVID-19 symptoms, four developed severe forms of the disease, with life-threatening pulmonary manifestations requiring intensive mechanical ventilation (RTX: 4 of 10, IFX: 0 of 11, Fisher's exact test p=0.04). The incidence rate of COVID-19 symptoms was 0.73 (95% CI 0.39 to 1.37) cases per 1000 patient-days on RTX vs 1.52 (95% CI 0.82 to 2.85) cases per 1000 patient-days on IFX (crude p=0.10, adjusted p=0.07). The incidence rate of severe COVID-19 was 0.28 (95% CI 0.08 to 0.7.2) cases per 1000 patient-days on RTX compared with null on IFX (95% CI 0.0 to 0.44) (p=0.13). A replication in an independent validation cohort confirmed these findings, with consistent results in the Swiss Clinical Quality Management registry. CONCLUSION: While the incidence of symptoms compatible with COVID-19 was overall similar in patients receiving RTX or IFX, the incidence of severe COVID-19 tended to be higher in the RTX group.